Program
Hadlima
Its studies are led by Biora Therapeutics.
Furthest: phase 1, since Sep 24, 20261 company-led study, 1 open or runningNext primary completion: Jan 15, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Biora Therapeutics | 11 open or running | phase 1since Sep 24, 2026 | Sep 24, 2026 | Jan 15, 2027phase 1 · NCT07849153 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 24, 2026First study: phase 1 study in Healthy SubjectsFirst studyNCT07849153 · 30 planned
Ahead
- Jan 15, 2027Primary completion: phase 1 study in Healthy SubjectsNCT07849153
TargetBeta
TNF →read by rule
“TNF-alpha inhibitor”ChEMBL 37, by rule
Other programs on TNF
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Adalimumabrule | Abbott | phase 4 | 153 |
| Brentuximab Vedotinrule | Pfizer | phase 4 | 37 |
| CHS-1420rule | nanjing-king-friend-biochemical-pharmaceutical-co-ltd | phase 3 | 2 |
| brivekimig | Sanofi | phase 2 | 6 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07849153Healthy Subjects | 1 | Not yet recruiting | Jan 15, 2027 | 30 |
How it is read
Names in the registry
- “Hadlima®”, 3 entries
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.